Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX)

Page 1 of 2

A couple of companies have had a tough twenty-four hours in the biotech space. One discontinuation, and another primary endpoint miss, has served up double digit losses in the companies in question, and both look set for further losses as we close in on the end of the week.

Here’s what happened.

The companies in question are Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Tenax Therapeutics Inc (NASDAQ:TENX). We’ll kick things off with Alnylam, as this is the major news of the day.

pharmacist, senior, man, talking, helpful, nhs, helping, counter, medication, older, american, drugs, woman, shelves, male, pack, usa, medical, practice, horizontal, adult,

Monkey Business Images/

The company has been developing what looks like a pretty robust pipeline of what are called RNAi therapeutics, or RNA interference drugs. This class of drugs was hailed as being a potential game changer across a variety of target indications as near term as just a couple of years ago. Some big names picked up programs, however they subsequently dropped these programs and moved on. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was one of the few that stuck with the drug class, and the biggest of the bunch, and it pretty much gambled its future on RNAi.

Fats forward to last night, and the company announced that it was dropping one of its lead programs, a phase III trial investigating the efficacy of a drug called revusiran in a rare disease target called hereditary transthyretin-related amyloidosis (hATTR) with cardiomyopathy (hATTR-CM).

Right now, we don’t know much. All we know is that the data monitoring committee that was tasked with keeping an eye on the study brought to light some concerning death rates (and recommended halting dosing), and that on analysis of these rates, the company has decided to discontinue the study entirely. Reportedly, eighteen deaths out of a total of a little over 200 patients occurred, and there was some unusually high level of nerve pain in patients in the active arm.

On the news, markets have traded down on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), and the company is currently trading close to 50% down on its Wednesday evening close. How this is going to play out, nobody is quite sure. The company still has a number of RNAi programs ongoing, and there looks to be some promise in these. If this turns out to be the case, the 50% hit will probably turn out to be an oversell. It’s a real gamble right now, however. It’s another in the long list of failures already racked up in RNAi, and the number of potential positive plays is dwindling.

Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Trade (NASDAQ:ALNY) Now!

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!